Improving muscle metabolism in prediabetes using SGLT2 inhibitors
Use of SGLT2 inhibition to improve skeletal muscle metabolism in prediabetes
This study is looking at how a type of medication called SGLT2 inhibitors, which helps control blood sugar in people with type 2 diabetes, might also help improve muscle health and metabolism in those with prediabetes, so if you're at risk for diabetes, this research could be for you!
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon State University NIH-funded |
| Lab location | 1 site (Corvallis, United States) |
| Project ID | NIH-10834043 on NIH RePORTER |
What this research studies
This research investigates how SGLT2 inhibitors, commonly used to manage blood sugar levels in type 2 diabetes, can enhance muscle metabolism in individuals with prediabetes. The study aims to understand the mechanisms by which these inhibitors improve insulin action in skeletal muscle, potentially leading to better glucose management. By examining changes in fat metabolism and mitochondrial function in muscle tissue, the research seeks to identify therapeutic benefits before the onset of diabetes. Participants may undergo assessments involving muscle biopsies and metabolic evaluations to gather data on the effects of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with prediabetes.
Not a fit: Patients who are not diagnosed with prediabetes or those with established type 2 diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve muscle metabolism and prevent the progression from prediabetes to type 2 diabetes.
How similar studies have performed: Previous studies have shown promising results with SGLT2 inhibitors in improving metabolic functions, indicating potential for success in this novel application.
Where this research is happening
Corvallis, United States
- Oregon State University — Corvallis, United States (Active)
Researchers
- Principal investigator: Newsom, Sean a. — Oregon State University
- Study coordinator: Newsom, Sean a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.